<?xml version="1.0" encoding="UTF-8"?>
<ref id="B37-pathogens-08-00176">
 <label>37.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Roccatello</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Sciascia</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Rossi</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Solfietti</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Fenoglio</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Menegatti</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Baldovino</surname>
    <given-names>S.</given-names>
   </name>
  </person-group>
  <article-title>The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents</article-title>
  <source>Oncotarget</source>
  <year>2017</year>
  <volume>8</volume>
  <fpage>41764</fpage>
  <lpage>41777</lpage>
  <pub-id pub-id-type="doi">10.18632/oncotarget.16986</pub-id>
  <pub-id pub-id-type="pmid">28454112</pub-id>
 </element-citation>
</ref>
